trending Market Intelligence /marketintelligence/en/news-insights/trending/QHOfhvAs-Id7o-wcxqr0OQ2 content esgSubNav
In This List

Merck pauses patient enrollment in multiple myeloma Keytruda combo trials

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Merck pauses patient enrollment in multiple myeloma Keytruda combo trials

Merck & Co. Inc. paused new patient enrollment in two studies exploring Keytruda in combination with other therapies in multiple myeloma, a type of blood cancer, to better understand reports of death among those receiving Keytruda.

The company accepted an external data monitoring committee's recommendation to pause patient enrollment in studies, KEYNOTE-183 and KEYNOTE-185, to collect more information.

Patients enrolled in the two studies would continue to receive treatment while other studies of Keytruda continue unchanged, Merck said.

KEYNOTE-183 is a phase 3 study comparing pomalidomide, sold by Celgene Corp. as Pomalyst, and low-dose dexamethasone with Keytruda to pomalidomide and low-dose dexamethasone alone, in patients with refractory or relapsed and refractory multiple myeloma who have undergone at least two lines of prior treatment.

KEYNOTE-185, is a phase 3 study comparing lenalidomide and low-dose dexamethasone with Keytruda to lenalidomide, sold by Celgene as Revlimid, and low-dose dexamethasone alone, in patients with newly diagnosed and treatment-naive multiple myeloma who are ineligible for a transplant of their own stem cells.

Merck's Keytruda is approved for the treatment of melanoma, lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma and microsatellite instability-high cancer.